24-26 February 2020|The Westin Miyako Kyoto,Kyoto, Japan
THE ONLY EVENT IN ASIA PROVIDING THE LATEST SCIENCE, TECHNOLOGY AND PARTNERS TO ACCELERATE ANTIBODY & PROTEIN THERAPIES, ADCS, BISPECIFICS AND IMMUNO-ONCOLOGY
World-renowned scientists sharing the latest technologies, R&D and clinical data to fast-track your next-generation therapeutics towards commercial success
WHAT'S NEW FOR 2020?
New Technologies, R&D Advances and Clinical Data to Help you Fast-Track Next Generation Therapeutics to Market
- NEW! Workshop on Engineering Strategies for TCR and CAR T Cell Therapies
- NEW! World-Renowned Academic and Industry Keynotes
- NEW! Location in Kyoto, Japan
- EXPANDED! More Confirmed Speakers from Leading US and European Antibody Companies
- EXPANDED! More Science and Data - 80% of Speakers Are New This Year
- EXPANDED! Exhibit and Poster Sessions
The Latest Scientific Case Studies and Data from Global Companies at the Forefront of Discovery
- Invenra, Amgen, Argenx, Xencor, Immatics and AbbVie will present breakthrough case studies and cutting-edge data
- Eisai will unveil the latest development of Novel Anti-Tau Antibody
- NBE-Therapeutics will provide an update on NBE-002, an anthracycline-based immune-stimulatory antibody drug conjugate
- Sai Reddy will uncover his data on how deep learning enables therapeutic antibody optimization in mammalian cells
- Genentech will detail MerTK Blockade which enhances anti-tumor immunity
- Dainippon Sumitomo's Antibody Intracellular Activated Drug Conjugate (AiADC) as a novel ADC technology
Novel Approaches to Accelerate Therapeutic Development To Be Covered
- Sally Ward’s Research on Targeting Intracellular Trafficking Pathways for the Design of Therapeutics
- Shohei Koide’s Advances in Novel Therapeutics Based on Synthetic Binding Proteins
- Lava Therapeutics’ Novel Bispecific γδ-T cell Engagers for the Treatment of Cancer
- Chugai’s Novel Antibody Engineering to Improve Therapeutic Index of Antibody Targeting Solid Tumors
- Takeda’s Vision for Antibody Drug Discovery: An Overview of Programs and Progress
- Koji Tamada’s Prime CAR Technology, a Novel Platform of T cell Therapy Against Solid Tumors
New Data and Science Presented by Foremost Authorities From Around the World
Get Global Recognition of Your Work by Presenting a Scientific Poster
- FOCUSED DISCUSSIONS: Posters offer the opportunity to engage with others also interested in the same subject and application as yourself which could potentially lead to future collaboration.
- RECEIVE IMPARTIAL CRITIQUES: An insightful, impartial discussion of your work by a peer can often provide ideas for improving your work downstream.
- HONE YOUR IDEAS: A poster is ideal for early stages of the research, when you may not have much more than an idea, and you stand to benefit a lot from discussing your idea with other researchers from the same field
Deadline to Submit a Poster is 24 January 2020
1 Registration = 2 Events
Your registration to Antibody Engineering & Therapeutics ASIA also accesses AsiaTIDES: Oligonucleotides and Peptide Therapeutics
24-26 February 2020 - The Westin Miyako Kyoto Hotel
Venue
The Westin Miyako Kyoto
1 Awataguchi Kachocho, Higashiyama-ku
Kyoto, 605-0052, Japan
+81 75-771-7111
Meet the Esteemed Scientific Advisory Board
- Tomoyuki Igawa, Ph.D., CEO and Research Head, Chugai Pharmabody Research Pte. Ltd., Singapore
- Qing Li, Ph.D., Scientist I, Medimmune, USA
- Sai Reddy, Ph.D., Assistant Professor, ETH Zurich, Switzerland
- Jijie Gu, Ph.D., Chief Scientific Officer and Executive Vice President,
WuXi Biologics, China - Chengbin Wu, Ph.D., Chief Executive Officer, Shanghai EpimAb Biotherapeutics Inc., China
- Yong-Sung Kim, Ph.D., Professor, Departments of Molecular Science and Technology, and Applied Chemistry and Biological Engineering, Ajou University, South Korea
- Karthik Viswanathan, Director, Research, Visterra, Inc., USA
- Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, Specifica, USA
